Free tool
FAERS Monitor: Cardura Xl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021269 or its brand name (Cardura Xl, Doxazosin Mesylate). Reports on generic versions are filed under their own applications.
Reports
15,500
Serious
12,187
79% of reports
Hospitalization
6,573
Death reported
1,476
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea882
- fatigue762
- dizziness744
- diarrhoea726
- drug ineffective714
- asthenia695
- nausea628
- hypotension623
- headache523
- hypertension522
- fall487
- pain469
- death463
- drug interaction461
- vomiting449
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 595 |
| 2005 | 514 |
| 2006 | 575 |
| 2007 | 738 |
| 2008 | 652 |
| 2009 | 708 |
| 2010 | 878 |
| 2011 | 1,142 |
| 2012 | 999 |
| 2013 | 471 |
| 2014 | 598 |
| 2015 | 738 |
| 2016 | 694 |
| 2017 | 572 |
| 2018 | 758 |
| 2019 | 694 |
| 2020 | 619 |
| 2021 | 610 |
| 2022 | 775 |
| 2023 | 584 |
| 2024 | 655 |
| 2025 | 540 |
| 2026 | 391 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,659 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypotensionSignal | 623 | 4.2 | 3.9 | 1,540 |
| drug interactionSignal | 461 | 4.0 | 3.6 | 1,018 |
| hypertensionSignal | 522 | 3.4 | 3.1 | 865 |
| astheniaSignal | 695 | 2.5 | 2.3 | 641 |
| dyspnoeaSignal | 882 | 2.1 | 2.0 | 531 |
| dizzinessSignal | 744 | 2.0 | 1.9 | 394 |
| fall | 487 | 2.0 | 1.8 | 241 |
| diarrhoea | 726 | 1.5 | 1.4 | 135 |
| fatigue | 762 | 1.3 | 1.2 | 64 |
| vomiting | 449 | 1.3 | 1.2 | 31 |
| headache | 523 | 1.1 | 1.0 | 8 |
| nausea | 628 | 1.1 | 1.0 | 3 |
| pain | 469 | 1.0 | 0.9 | 1 |
| drug ineffective | 714 | 0.7 | 0.7 | 72 |
| death | 463 | 0.7 | 0.7 | 48 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.